Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19
Status:
Recruiting
Trial end date:
2021-09-05
Target enrollment:
Participant gender:
Summary
This is an exploratory study to evaluate the efficacy of Doxycycline (200mg on D1 to D7) and
Rivaroxaban (15 mg daily on D1 to D7) versus the combination of Hydroxychloroquine (400 mg on
D1 to D7) and Azithromycin (500 mg on D1 and 250mg on D2 to D5) as per national standard to
treat ambulatory mild COVID-19 patients, with the aim to achieve early negativity of RT-PCR
of SARS-CoV-2 from nasopharyngeal swab, and early clinical improvement and prevention of
severe disease.